Pyrrolizidine (±)-2, the bridgehead-methyl analog of SC-53116, was prepared and evaluated for 5-HT 4 agonism activity in the rat tunica muscularis (TMM) mucosae assay. Compound (±)-2 has an EC 50 of 449 nM in the TMM assay, as compared to 23 nM for SC-53116, and 66 nM for the racemate of SC-53116.
Abstract-Pyrrolizidine benzamide (±)-2, the bridgehead-methyl analog of SC-53116, was prepared and evaluated for 5-HT 4 agonism activity in the rat tunica muscularis (TMM) mucosae assay. Compound (±)-2 has an EC 50 of 449 nM in the TMM assay, as compared to 23 nM for SC-53116, and 66 nM for the racemate of SC-53116.
We have previously reported our discovery of SC-53116, which was the first selective agonist at the 5-HT 4 receptor. 1 SC-53116 has an ED 50 of 23 nM in the tunica muscularis mucosae assay of Craig and Clarke, 2 and is selective versus other monoamine receptors with a K i of 152 nM at the 5-HT 3 receptor and K i 's of >10,000 nM at the 5-HT 1 , 5-HT 2 , D 1 , D 2 , α 1 , α 2 and β-receptors. The 5-HT 4 receptor was discovered by Clark 2 and Bockaert 3 in the brain and gut, respectively, and is expressed in a wide variety of tissues including brain, heart, bladder, gut and kidney. 4 Selective ligands for the receptor show promise in the treatment of diseases including the irritable bowel syndrome, atrial arrhythmia, urinary incontinence, and gastrointestinal motility disorders. An excellent review of the 5-HT 4 receptor and key ligands was recently published. 5 We have been interested in pursuing 5-HT 4 agonists as gastrointestinal prokinetic agents. Our efforts in this area 6 have also prompted us to develop several azatricyclic benzamides 7 that are potent 5-HT 4 agonists and 5-HT 3 antagonists, particularly SC-52491, 8 in addition to the pyrrolizidine SC-53116. 
SC-52491
N H SC-53116 was a clinical candidate but was halted when it was observed to be positive in the Ames assay when tested with S9 activation. 9 We hypothesized that this toxicity was due to oxidation of the pyrrolizidine moiety to the bicyclic iminium ion 1, which can then function as an alkylating agent. To avoid this liability, we targeted the bridgehead-methyl SC-53116 analog (±)-2, as the methyl group would block metabolism to the iminium species. We targeted the racemate initially to test the concept and ensure that sufficient potency is maintained with the additional methyl group.
We employed general methodology reported by Meyers 10 for introduction of the requisite quaternary carbon at the pyrrolizidinone bridgehead position. As outlined in Scheme 1, ketoester 3 was heated under reflux with ethanolamine to afford (±)-4 11 in 53% yield. The bicyclic lactam (±)-4 was treated with t-butyldimethylsilyl methyl acetate ketal 12 in 2M lithium perchlorate ether 13 to afford lactam (±)-5 in 30% yield. Attempts with titanium tetrachloride in methylene chloride also afforded (±)-5 but in lower yield. The primary alcohol of (±)-5 was converted to the tosylate in 86% yield by treating with tosyl chloride in pyridine. Treatment of the tosylate with sodium iodide under Finkelstein conditions afforded the primary iodide (±)-6. A variety of bases were employed to effect closure of (±)-6, with potassium hexamethyldisilazide giving the best yield of (±)-7 and (±)-8 in a combined 70% yield. The exo and endo methyl esters were isolated in a 1:2 ratio, with the endo (±)-8 as the main component, as determined by NOE. 14 Reduction with lithium aluminum hydride gave a mixture of alcohols (±)-9 and (±)-10, and this mixture was converted directly to the phthalimides under Mitsunobu conditions, allowing chromatographic isolation of the requisite exo isomer (±)-11 in 24% yield. Deprotection of (±)-11 with hydrazine gave the free amine in quantitative yield which was coupled directly with 5-acetamido-4-chloro-2methoxybenzoic acid utilizing carbonyl diimidazole to afford the desired benzamide. The acetamide was removed with potassium hydroxide in ethanol under reflux to afford the desired benzamide isomer (±)-2 in 66% yield.
Thus (±)-2, the bridgehead-methyl analog of SC-53116, was tested for agonist activity at the 5-HT 4 receptor in the rat tunica muscularis mucosae assay. The potency for the compound was good, at 449 nM (± 185). However, this was approximately 7X less potent than SC-49518, the racemate of SC-53116, which has an EC50 of 66 nM ±11 nM. Due to the loss of potency, the bridgehead methyl analog (±)-2 was not pursued further. The azatricycle benzamide compounds that we developed 7,8 are potent, efficacious, and safe, so we turned our attention to those molecules. Specifically, SC-52491 was negative in the Ames assay at the highest concentrations tested, either with or without S9 activation. 15 
